Performance in Delivering Clinical Trials - Q2 2018/19

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date agreed to recruit target number of participants	Total Number Of patients Recruited at the agreed date	Total Number Of Study Participants Recruited	Date that the trial closed to recruitment	Reason For Closure Of Trial
17/LO/0683	222836	A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-659 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis	Number Agreed	1	1	Date Agreed	28/02/2018	1	1	17/11/2017	Recruitment Finished
17/EE/0090	202344	A Phase IIa, randomized, double-blind, placebo-controlled study to evaluate multiple doses of GLPG2222 in subjects with Cystic Fibrosis who are homozygous for the F508del mutation.	Number Agreed	1	1	Date Agreed	01/10/2017	1	1	12/12/2017	Recruitment Finished
16/EE/0235	126333	BI 1199.36 - A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib co-administered with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibr	Number Agreed	3	3	Date Agreed	08/03/2018	3	3	12/12/2017	Recruitment Finished
13/WM/0235	199081	Atrial Fibrillation Progression Trial (ATTEST)	Number Agreed	15	15	Not Available / Not Agreed			1	20/12/2017	Recruitment Finished
16/LO/1766	212839	A Phase IIa, randomised, double blind, placebo controlled, three way crossover study to assess the pharmacokinetics of RPL554 administered to adult patients with Cystic Fibrosis.	Number Agreed	15	15	Date Agreed	02/04/2017	10	10	10/11/2017	Recruitment Finished
16/EE/0358	218716	A randomized, blinded, parallel group, multi-center dose-finding study, to assess the efficacy, safety and tolerability of different doses of tobramycin inhalation powder in patients with Non-Cystic Fibrosis Bronchiectasis and pulmonary P. aeruginosa infec	Number Agreed	3	3	Date Agreed	01/03/2019	2	2	31/08/2018	Withdrawn By Sponsor
17/EE/0502	199081	Long-term, open label, multicenter, extension study to evaluate the safety and tolerability of QCC374 in patients with PAH	Number Agreed	2	2	Date Agreed	05/09/2018	2	2	05/09/2018	Recruitment Finished